Nov 16 (Reuters) – AstraZeneca said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)